Jan. 31 at 4:03 PM
$FBIO Using a very blunt valuation method (assume common and preferred shares have equal ownership, add the Fortress specific cash following subtraction of the public company cash and then add the narket value of the public company shares owned) I get a number of 3.21. That doesn’t take into consideration debt, PRV, revenues, Sentynl shares or any other variables.
This tells me the company is very undervalued. I think a combination of the preferred dividend default, the debt, the complex ownership structure, the quiet management and the fact that huge catalysts (prv receipt and expected proceeds) are not yet available in published finances mean that the market is behind the curve. I noticed that in 2025 the price was generally trading in a range until the Q3 earnings spelled out in black ink what the Checkpoint sale meant, and I think we are seeing the same again. I think whichever 10-Q reflects the PRV sale this year is going to be the shot in the arm the stock needs.
